NCT02368860View on ClinicalTrials.gov

OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 17, 2013

Primary Completion Date

May 21, 2020

Study Completion Date

May 21, 2020

Conditions
Pancreatic Cancer
Interventions
DRUG

oxaliplatin, irinotecan, capecitabine

fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14

Trial Locations (1)

169610

National Cancer Centre, Singapore

All Listed Sponsors
collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

National Cancer Centre, Singapore

OTHER

NCT02368860 - OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter